98 related articles for article (PubMed ID: 21250872)
1. Advances in human papilloma virus vaccines: a patent review.
Cho HJ; Oh YK; Kim YB
Expert Opin Ther Pat; 2011 Mar; 21(3):295-309. PubMed ID: 21250872
[TBL] [Abstract][Full Text] [Related]
2. Production of human papillomavirus type 33 L1 major capsid protein and virus-like particles from Bacillus subtilis to develop a prophylactic vaccine against cervical cancer.
Baek JO; Seo JW; Kwon O; Park SM; Kim CH; Kim IH
Enzyme Microb Technol; 2012 Mar; 50(3):173-80. PubMed ID: 22305172
[TBL] [Abstract][Full Text] [Related]
3. Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination.
Vandepapeliere P; Barrasso R; Meijer CJ; Walboomers JM; Wettendorff M; Stanberry LR; Lacey CJ
J Infect Dis; 2005 Dec; 192(12):2099-107. PubMed ID: 16288373
[TBL] [Abstract][Full Text] [Related]
4. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
Mejia AF; Culp TD; Cladel NM; Balogh KK; Budgeon LR; Buck CB; Christensen ND
J Virol; 2006 Dec; 80(24):12393-7. PubMed ID: 17005666
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against Chlamydia trachomatis genital infection induced by a vaccine based on the major outer membrane multi-epitope human papillomavirus major capsid protein L1.
Xu W; Liu J; Gong W; Chen J; Zhu S; Zhang L
Vaccine; 2011 Mar; 29(15):2672-8. PubMed ID: 21324344
[TBL] [Abstract][Full Text] [Related]
6. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
7. In silico DNA vaccine designing against human papillomavirus (HPV) causing cervical cancer.
Gupta SK; Singh A; Srivastava M; Gupta SK; Akhoon BA
Vaccine; 2009 Dec; 28(1):120-31. PubMed ID: 19799841
[TBL] [Abstract][Full Text] [Related]
8. Virus-like particle vaccines and adjuvants: the HPV paradigm.
Buonaguro FM; Tornesello ML; Buonaguro L
Expert Rev Vaccines; 2009 Oct; 8(10):1379-98. PubMed ID: 19803760
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies.
Xie X; Liu Y; Zhang T; Xu Y; Bao Q; Chen X; Liu H; Xu X
Arch Virol; 2013 Jan; 158(1):193-9. PubMed ID: 22965579
[TBL] [Abstract][Full Text] [Related]
10. Prophylactic DNA immunization against multiple papillomavirus types.
Gasparić M; Rubio I; Thönes N; Gissmann L; Müller M
Vaccine; 2007 Jun; 25(23):4540-53. PubMed ID: 17485151
[TBL] [Abstract][Full Text] [Related]
11. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions.
Chen J; Ni G; Liu XS
Cell Immunol; 2011; 269(1):5-9. PubMed ID: 21477796
[TBL] [Abstract][Full Text] [Related]
12. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
Villa LL
Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
[TBL] [Abstract][Full Text] [Related]
14. The human papillomavirus vaccines.
Ljubojević S
Acta Dermatovenerol Croat; 2006; 14(3):208. PubMed ID: 17010274
[TBL] [Abstract][Full Text] [Related]
15. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum.
Kohl TO; Hitzeroth II; Christensen ND; Rybicki EP
BMC Biotechnol; 2007 Sep; 7():56. PubMed ID: 17850660
[TBL] [Abstract][Full Text] [Related]
16. Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.
Kondo K; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
J Med Virol; 2008 May; 80(5):841-6. PubMed ID: 18360909
[TBL] [Abstract][Full Text] [Related]
17. Insights into the role and function of L2, the minor capsid protein of papillomaviruses.
Pereira R; Hitzeroth II; Rybicki EP
Arch Virol; 2009; 154(2):187-97. PubMed ID: 19169853
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus L1 protein expressed in tobacco chloroplasts self-assembles into virus-like particles that are highly immunogenic.
Fernández-San Millán A; Ortigosa SM; Hervás-Stubbs S; Corral-Martínez P; Seguí-Simarro JM; Gaétan J; Coursaget P; Veramendi J
Plant Biotechnol J; 2008 Jun; 6(5):427-41. PubMed ID: 18422886
[TBL] [Abstract][Full Text] [Related]
19. Purification and immunogenicity study of human papillomavirus 58 virus-like particles expressed in Pichia pastoris.
Jiang Z; Tong G; Cai B; Xu Y; Lou J
Protein Expr Purif; 2011 Dec; 80(2):203-10. PubMed ID: 21821128
[TBL] [Abstract][Full Text] [Related]
20. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
